Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5455208 | 0.89 | THRB (0.47) | THRBLMNAMAPK1HTTPOLB | |
| SCHEMBL5449813 | 0.89 | MAPT (0.43) | LMNAPOLBKMT2AMAPTHPGD | |
| SCHEMBL5465837 | 0.83 | USP2 (0.49) | LMNAMAPK1HTTPOLBGAA | |
| SCHEMBL5446219 | 0.81 | KMT2A (0.45) | LMNAMAPK1HTTPTGDR2KMT2A | |
| SCHEMBL5455125 | 0.79 | LMNA (0.51) | LMNAPOLBKMT2AMAPTHPGD | |
| SCHEMBL5452488 | 0.79 | LMNA (0.42) | LMNAMAPK1HTTPOLBGAA | |
| SCHEMBL5459211 | 0.78 | ALDH1A1 (0.52) | LMNAMAPK1HTTGAAPTGDR2 | |
| SCHEMBL5451045 | 0.78 | MAPT (0.45) | LMNAMAPK1HTTPOLBGAA | |
| SCHEMBL5450989 | 0.78 | GAA (0.52) | LMNAMAPK1HTTGAAHSD17B10 | |
| SCHEMBL14596936 | 0.78 | HTR1A (0.48) | THRBLMNAPOLBHTR6L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | HTR1B, HTR1D, HTR1A | THRB 1039/4885LMNA 1833/4885MAPK1 3018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.